Historique de carrière de Ronald Guido
Anciens postes connus de Ronald Guido
Sociétés | Poste | Début | Fin |
---|---|---|---|
ETERNA THERAPEUTICS INC. | Directeur Général | 01/03/2020 | 16/04/2021 |
Corporate Officer/Principal | 16/04/2021 | 31/12/2021 | |
Eterna Therapeutics LLC
Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | Directeur Général | 01/03/2020 | 25/03/2021 |
Corporate Officer/Principal | 01/11/2018 | 25/03/2021 | |
IRX Therapeutics, Inc.
IRX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology IRX Therapeutics, Inc. provides pharmaceutical products. Its therapies are designed to target and restore the immune system in order to improve a patient's response to next-generation cancer vaccines and novel targeted therapeutics. The company was founded in 1994 and is headquartered in New York, NY. | Conseiller Juridique Général | 01/01/2017 | 01/12/2020 |
VELOXIS PHARMACEUTICALS A/S | Compliance Officer | 01/01/2010 | 01/12/2016 |
Conseiller Juridique Général | 01/01/2010 | 01/12/2016 | |
TRAVERE THERAPEUTICS, INC. | Conseiller Juridique Général | 28/10/2013 | 01/06/2014 |
PFIZER, INC. | Directeur/Membre du Conseil | - | - |
Formation de Ronald Guido
Caldwell College | Undergraduate Degree |
Royal Hibernian Academy | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 8 |
Danemark | 2 |
Irlande | 2 |
Opérationnelle
General Counsel | 3 |
Graduate Degree | 2 |
Chief Executive Officer | 2 |
Sectorielle
Health Technology | 7 |
Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
PFIZER, INC. | Health Technology |
TRAVERE THERAPEUTICS, INC. | Health Technology |
ETERNA THERAPEUTICS INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
IRX Therapeutics, Inc.
IRX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology IRX Therapeutics, Inc. provides pharmaceutical products. Its therapies are designed to target and restore the immune system in order to improve a patient's response to next-generation cancer vaccines and novel targeted therapeutics. The company was founded in 1994 and is headquartered in New York, NY. | Health Technology |
Polytechnic University | Consumer Services |
Eterna Therapeutics LLC
Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | Health Technology |
- Bourse
- Insiders
- Ronald Guido
- Expérience